{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:35:27Z","timestamp":1790411727657,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Statins have long been the cornerstone for the prevention of cardiovascular disease (CVD). However, because of perceived adverse effects and insufficient efficacy in certain groups of patients, considerable interest exists in the search for alternatives to lower LDL-cholesterol (LDL-C), and the recent approvals of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors underlines the success of this quest. Here, we give an updated overview on the most recent developments in the area of LDL-C lowering agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The clinical effects of the PCSK9 inhibitors are promising, especially now that the FOURIER and SPIRE programmes are published. Most cholesterylester-transfer protein inhibitors, however, except anacetrapib, have been discontinued because of either toxicity or lack of efficacy in large cardiovascular outcome trials. Other agents \u2013 like mipomersen, lomitapide, ETC-1002, and gemcabene \u2013 aim to lower LDL-C in different ways than solely through the LDL receptor, opening up possibilities for treating patients not responding to conventional therapies. New discoveries are also being made at the DNA and RNA level, with mipomersen being the first approved therapy based on RNA intervention in the United States for homozygous familial hypercholesterolemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Recent years have witnessed a new beginning for cholesterol-lowering compounds. With increased knowledge of lipid metabolism a score of new therapeutic targets has been identified. Mechanisms for modulation of those targets are also becoming more diverse while statins remain the backbone of CVD prevention, the new alternatives, such as PCSK9 monoclonals will probably play an important additional role in treatment of patients at risk for CVD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000428","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T16:14:49Z","timestamp":1493136889000},"page":"367-373","source":"Crossref","is-referenced-by-count":25,"title":["Novel lipid modifying drugs to lower LDL cholesterol"],"prefix":"10.1097","volume":"28","author":[{"given":"Arjen J.","family":"Cupido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens F.","family":"Reeskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"861924","DOI":"10.1155\/2012\/861924","article-title":"Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients","volume":"2012","author":"Karalis","year":"2012","journal-title":"Cholesterol"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"R8-20230917","first-page":"1","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-20230917","article-title":"The ACCELERATE trial: impact of the cholesteryl ester transfer protein inhibitor evacetrapib on cardiovascular outcome. Present. 65th Annu. Sci. Sess. Expo Am. Coll","author":"Nicholls","year":"2016","journal-title":"Cardiol"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1152\/ajpendo.00528.2014","article-title":"New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism","volume":"309","author":"Miyosawa","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4093\/dmj.2015.39.2.87","article-title":"New drugs for treating dyslipidemia: beyond statins","volume":"39","author":"Ahn","year":"2015","journal-title":"Diabetes Metab J"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5551\/jat.38216","article-title":"Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia","volume":"24","author":"Harada-Shiba","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5551\/jat.30452","article-title":"Pharmacokinetics and pharmacodynamics of lomitapide in Japanese subjects","volume":"23","author":"Taubel","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jcph.581","article-title":"Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol\/norgestimate on lomitapide pharmacokinetics in healthy subjects","volume":"56","author":"Patel","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jphs.2015.10.004","article-title":"JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates lipid metabolism and attenuates atherosclerosis in hyperlipidemic animal models","volume":"129","author":"Mera","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"Am J Cardiol"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jacl.2016.08.002","article-title":"Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients","volume":"10","author":"Stein","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9149(03)00721-5","article-title":"Gemcabene study group effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol","volume":"92","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"E513","DOI":"10.1208\/aapsj070352","article-title":"Model-based development of gemcabene, a new lipid-altering agent","volume":"7","author":"Mandema","year":"2005","journal-title":"AAPS J"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur Heart J"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jacl.2014.08.002","article-title":"Liver histology during Mipomersen therapy for severe hypercholesterolemia","volume":"8","author":"Hashemi","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","article-title":"Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"A long-term (up to 6 years) retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency (LPLD)-induced pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Hum Gene Ther"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-016-0579-0","article-title":"Recent developments in gene therapy for homozygous familial hypercholesterolemia","volume":"18","author":"Ajufo","year":"2016","journal-title":"Curr Atheroscler Rep"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201708000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:11:15Z","timestamp":1694938275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201708000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000428","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}